Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMY Analyst Ratings

Hold

5 Buy

13 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

CHF40.57

▼(-25.20% Downside)

Based on 19 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is CHF40.57 with a high forecast of CHF51.71 and a low forecast of CHF27.05. The average price target represents a -25.20% change from the last price of CHF54.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"CHF26","55":"CHF55","33.25":"CHF33.3","40.5":"CHF40.5","47.75":"CHF47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51.7054447,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF51.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.56888738,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF40.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.04592492,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF27.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,33.25,40.5,47.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.24,54.04503420769231,53.85006841538462,53.65510262307693,53.46013683076923,53.26517103846154,53.07020524615385,52.875239453846156,52.680273661538465,52.48530786923077,52.290342076923075,52.095376284615384,51.90041049230769,{"y":51.7054447,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.24,53.188375952307695,52.13675190461539,51.08512785692308,50.03350380923077,48.981879761538465,47.93025571384616,46.87863166615385,45.827007618461536,44.775383570769236,43.72375952307692,42.672135475384614,41.62051142769231,{"y":40.56888738,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.24,52.14814807076923,50.05629614153846,47.9644442123077,45.872592283076926,43.780740353846156,41.688888424615385,39.597036495384614,37.505184566153844,35.41333263692307,33.32148070769231,31.22962877846154,29.137776849230768,{"y":27.04592492,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.24,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF51.71

Average Price TargetCHF40.57

Lowest Price TargetCHF27.05

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

CHF46.15

Hold

-14.92%

Downside

Assigned

10/21/25

Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

10/20/25

Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)

David Amsellem

Piper Sandler

CHF50.92

Buy

-6.12%

Downside

Reiterated

10/20/25

Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Bristol-Myers Squibb (BMY)Reiterating our Overweight rating with a new PT of $64 as recent data comes into focus.

Asad Haider

Goldman Sachs

CHF44.56→CHF40.58

Hold

-25.19%

Downside

Reiterated

10/20/25

Bristol-Myers Squibb: Hold Rating Amid Market Challenges and Uncertain Growth Prospects

Tim Anderson

Bank of America Securities

CHF39.78

Hold

-26.65%

Downside

Reiterated

10/16/25

Neutral Outlook for Bristol-Myers Squibb Amidst Competitive Pressures and Growth Challenges

Veda Pharmyne

TR | OpenAI - 4o

CHF42.17→CHF37.4

Hold

-31.05%

Downside

Reiterated

10/16/25

AI Generated ArticleAI Generated Article

David Risinger

Leerink Partners

CHF42.17

Buy

-22.25%

Downside

Reiterated

10/14/25

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Aclaris Therapeutics (NASDAQ: ACRS)

Mohit Bansal

Wells Fargo

CHF42.17

Hold

-22.25%

Downside

Reiterated

10/13/25

Wells Fargo Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Dane Leone

Raymond James

―

Hold

―

Reiterated

10/13/25

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Alcon (NYSE: ALC)We maintain our Market Perform rating.

Geoff Meacham

Citi

CHF37.4→CHF38.19

Hold

-29.59%

Downside

Reiterated

10/10/25

Bristol Myers price target raised to $48 from $47 at CitiBristol Myers price target raised to $48 from $47 at Citi

Evan Seigerman

BMO Capital

CHF37.4

Hold

-31.05%

Downside

Reiterated

10/03/25

Hold Rating Issued for Bristol-Myers Squibb Amid Declining Cobenfy Prescriptions and Revenue Forecast Miss

Unknown Analyst

CFRA

Not Ranked

CFRA

CHF43.76

Buy

-19.32%

Downside

Upgraded

10/01/25

Positive Report for Bristol-Myers Squibb (BMY) from CFRA

Terence Flynn

Morgan Stanley

CHF27.05

Sell

-50.12%

Downside

Reiterated

09/30/25

Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (NYSE: BMY), Boston Scientific (NYSE: BSX) and Zenas BioPharma, Inc. (NASDAQ: ZBIO)

Matt Phipps

William Blair

―

Hold

―

Reiterated

09/23/25

Hold Rating Maintained for Bristol-Myers Squibb Amid Uncertainty in CELMoD Franchise Developments

Chris Schott

J.P. Morgan

CHF51.72

Buy

-4.65%

Downside

Reiterated

09/16/25

Bristol-Myers Squibb (BMY) Gets a Buy from J.P. Morgan

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

CHF46.15

Hold

-14.92%

Downside

Assigned

10/21/25

Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

10/20/25

Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)

David Amsellem

Piper Sandler

CHF50.92

Buy

-6.12%

Downside

Reiterated

10/20/25

Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Bristol-Myers Squibb (BMY)Reiterating our Overweight rating with a new PT of $64 as recent data comes into focus.

Asad Haider

Goldman Sachs

CHF44.56→CHF40.58

Hold

-25.19%

Downside

Reiterated

10/20/25

Bristol-Myers Squibb: Hold Rating Amid Market Challenges and Uncertain Growth Prospects

Tim Anderson

Bank of America Securities

CHF39.78

Hold

-26.65%

Downside

Reiterated

10/16/25

Neutral Outlook for Bristol-Myers Squibb Amidst Competitive Pressures and Growth Challenges

Veda Pharmyne

TR | OpenAI - 4o

CHF42.17→CHF37.4

Hold

-31.05%

Downside

Reiterated

10/16/25

AI Generated ArticleAI Generated Article

David Risinger

Leerink Partners

CHF42.17

Buy

-22.25%

Downside

Reiterated

10/14/25

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Aclaris Therapeutics (NASDAQ: ACRS)

Mohit Bansal

Wells Fargo

CHF42.17

Hold

-22.25%

Downside

Reiterated

10/13/25

Wells Fargo Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Dane Leone

Raymond James

―

Hold

―

Reiterated

10/13/25

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Alcon (NYSE: ALC)We maintain our Market Perform rating.

Geoff Meacham

Citi

CHF37.4→CHF38.19

Hold

-29.59%

Downside

Reiterated

10/10/25

Bristol Myers price target raised to $48 from $47 at CitiBristol Myers price target raised to $48 from $47 at Citi

Evan Seigerman

BMO Capital

CHF37.4

Hold

-31.05%

Downside

Reiterated

10/03/25

Hold Rating Issued for Bristol-Myers Squibb Amid Declining Cobenfy Prescriptions and Revenue Forecast Miss

Unknown Analyst

CFRA

Not Ranked

CFRA

CHF43.76

Buy

-19.32%

Downside

Upgraded

10/01/25

Positive Report for Bristol-Myers Squibb (BMY) from CFRA

Terence Flynn

Morgan Stanley

CHF27.05

Sell

-50.12%

Downside

Reiterated

09/30/25

Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (NYSE: BMY), Boston Scientific (NYSE: BSX) and Zenas BioPharma, Inc. (NASDAQ: ZBIO)

Matt Phipps

William Blair

―

Hold

―

Reiterated

09/23/25

Hold Rating Maintained for Bristol-Myers Squibb Amid Uncertainty in CELMoD Franchise Developments

Chris Schott

J.P. Morgan

CHF51.72

Buy

-4.65%

Downside

Reiterated

09/16/25

Bristol-Myers Squibb (BMY) Gets a Buy from J.P. Morgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

1 Month

xxx

Success Rate

12/25 ratings generated profit

Average Return

+0.54%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.00% of your transactions generating a profit, with an average return of +0.54% per trade.

3 Months

xxx

Success Rate

16/25 ratings generated profit

Average Return

+2.50%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.00% of your transactions generating a profit, with an average return of +2.50% per trade.

1 Year

Terence FlynnMorgan Stanley

Success Rate

21/25 ratings generated profit

Average Return

+9.78%

reiterated a sell rating 27 days ago

Copying Terence Flynn's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +9.78% per trade.

2 Years

xxx

Success Rate

23/25 ratings generated profit

Average Return

+14.72%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.00% of your transactions generating a profit, with an average return of +14.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMY has received 10 Buy Ratings, 24 Hold Ratings, and 1 Sell Ratings. BMY average Analyst price target in the past 3 months is 40.57.

Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is CHF1.22 with a range of CHF1.08 to CHF1.44. The previous quarter’s EPS was CHF1.16. BMY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BMY has Preformed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is CHF9.40B with a range of CHF9.21B to CHF9.60B. The previous quarter’s sales results were CHF9.76B. BMY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BMY has Preformed in-line its overall industry.

BMY Stock Forecast FAQ

What is CH:BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 40.57.

What is CH:BMY’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:BMY, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bristol-Myers Squibb a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Hold, which is based on 5 buy ratings, 13 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s share price target?

The average share price target for Bristol-Myers Squibb is 40.57. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF51.71 ,and the lowest forecast is CHF27.05. The average share price target represents -25.20% Decrease from the current price of CHF54.24.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Bristol-Myers Squibb?

To buy shares of CH:BMY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

BMY Analyst Ratings

BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BMY Analyst Recommendation Trends

BMY Financial Forecast

BMY Earnings Forecast

BMY Sales Forecast

BMY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts